{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:07:09Z","timestamp":1789495629017,"version":"build-2803163510"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/ http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>To improve the prognosis of advanced intrahepatic cholangiocarcinoma (iCCA), the authors retrospectively compared the effect and safety of combined hepatic arterial infusion chemotherapy (HAIC), targeted therapy, and immunotherapy with systemic chemotherapy (SC) in unresectable iCCA patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The authors retrospectively enrolled 202 advanced iCCA patients treated with SC or targeted therapy, immunotherapy, and FOLFOX-HAIC combined between March 2015 and June 2023 at our institution. Two hundred two patients were divided into two groups based on the therapeutic regimens. Baseline characteristics and prognosis were reviewed and analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      After 1-to-1 propensity score matching, 76 patients were included in each group. The triple combination therapy group demonstrated longer median overall survival (OS, 20.77 vs. 14.83 months,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.047), progression-free survival (PFS, 9.07 vs. 6.23 months,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001), intrahepatic PFS (11.03 vs. 6.73 months,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001), extrahepatic PFS (11.37 vs. 7.13 months,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.0064), and a higher objective response rate (35.5% vs. 14.5%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.003) than the SC group. Fever, thrombocytopenia, elevated ALT, elevated AST, hypoalbuminemia, and hyperbilirubinemia were more common adverse events (AEs) in the triple combination therapy group, while fatigue and anemia were more prevalent in the SC group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.05). For grades 3-4 AEs, the rates of elevated ALT were higher in the triple combination group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.028).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Compared with SC, triple combination therapy comprising HAIC, targeted therapy and immunotherapy appears to be an effective and safe treatment for advanced iCCA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000002013","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T13:08:01Z","timestamp":1723036081000},"page":"1552-1557","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Hepatic arterial infusion chemotherapy plus targeted therapy and immunotherapy versus systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a retrospective cohort study"],"prefix":"10.1097","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4587-2665","authenticated-orcid":false,"given":"Zhikai","family":"Zheng","sequence":"first","affiliation":[{"name":"Department of Liver Surgery, Sun Yat-sen University Cancer Center"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiongliang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Sun Yat-sen University Cancer Center"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqing","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Sun Yat-sen University Cancer Center"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minrui","family":"He","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Sun Yat-sen University Cancer Center"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangxun","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Sun Yat-sen University Cancer Center"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juncheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Sun Yat-sen University Cancer Center"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Sun Yat-sen University Cancer Center"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Sun Yat-sen University Cancer Center"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Sun Yat-sen University Cancer Center"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaojun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Sun Yat-sen University Cancer Center"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minshan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Sun Yat-sen University Cancer Center"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongguo","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Sun Yat-sen University Cancer Center"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,1]]},"reference":[{"key":"R1-20260304","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","article-title":"Cholangiocarcinoma","volume":"383","author":"Razumilava","year":"2014","journal-title":"The Lancet"},{"key":"R2-20260304","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.soc.2019.06.002","article-title":"Intrahepatic cholangiocarcinoma","volume":"28","author":"El-Diwany","year":"2019","journal-title":"Surg Oncol Clin N Am"},{"key":"R3-20260304","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma - evolving concepts and therapeutic strategies","volume":"15","author":"Rizvi","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"R4-20260304","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","article-title":"Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma","volume":"60","author":"Bridgewater","year":"2014","journal-title":"J Hepatol"},{"key":"R5-20260304","doi-asserted-by":"crossref","first-page":"1260191","DOI":"10.3389\/fimmu.2024.1260191","article-title":"Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma","volume":"15","author":"Huang","year":"2024","journal-title":"Front Immunol"},{"key":"R6-20260304","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jhep.2018.02.008","article-title":"Hepatic arterial infusion of oxaliplatin plus fluorouracil\/leucovorin vs. sorafenib for advanced hepatocellular carcinoma","volume":"69","author":"Lyu","year":"2018","journal-title":"J Hepatol"},{"key":"R7-20260304","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3390\/cancers14020362","article-title":"Treatment of Intrahepatic Cholangiocarcinoma-A Multidisciplinary Approach","volume":"14","author":"Krenzien","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R8-20260304","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"R9-20260304","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/cam4.299","article-title":"Cisplatin\/gemcitabine or oxaliplatin\/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review","volume":"3","author":"Fiteni","year":"2014","journal-title":"Cancer Med"},{"key":"R10-20260304","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/annonc\/mdh351","article-title":"Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study","volume":"15","author":"Andre","year":"2004","journal-title":"Ann Oncol"},{"key":"R11-20260304","first-page":"200","article-title":"Advanced intrahepatic cholangiocarcinoma: post hoc analysis of the ABC-01, -02, and -03 clinical trials","volume":"112","author":"Lamarca","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"R12-20260304","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jamaoncol.2020.0340","article-title":"Locoregional therapy plus systemic chemotherapy in unresectable intrahepatic cholangiocarcinoma","volume":"6","author":"Yang","year":"2020","journal-title":"JAMA Oncol"},{"key":"R13-20260304","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13046-018-0777-4","article-title":"Immune checkpoint therapy in liver cancer","volume":"37","author":"Xu","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"R14-20260304","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/bjs\/znab410","article-title":"Targeted therapies in cholangiocarcinoma: emerging hope through novel trial design","volume":"109","author":"Guest","year":"2022","journal-title":"Br J Surg"},{"key":"R15-20260304","doi-asserted-by":"crossref","first-page":"894407","DOI":"10.3389\/fphar.2022.894407","article-title":"Lenvatinib combined with a PD-1 inhibitor as effective therapy for advanced intrahepatic cholangiocarcinoma","volume":"13","author":"Xie","year":"2022","journal-title":"Front Pharmacol"},{"key":"R16-20260304","doi-asserted-by":"crossref","first-page":"17588359211002720","DOI":"10.1177\/17588359211002720","article-title":"Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma","volume":"13","author":"He","year":"2021","journal-title":"Ther Adv Med Oncol"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000002013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T12:06:17Z","timestamp":1772625977000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000002013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000002013","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,7]]},"assertion":[{"value":"2024-04-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}